2-氨基-3-氯苯甲酸甲酯 | 77820-58-7

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-3-氯苯甲酸甲酯
• 中文别名: 2-氨基-3-氯苯甲酸甲脂
• 英文名称: methyl 3-chloroanthranilate
• 英文别名: methyl 2-amino-3-chlorobenzoate；2-Amino-3-chloro-benzoic acid methyl ester
• CAS: 77820-58-7
• 化学式: C₈H₈ClNO₂
• 分子量: 185.61
• InChiKey: MSXSZFYRADEEJA-UHFFFAOYSA-N

物化性质

• 熔点：
  35-37°C
• 沸点：
  273.8±20.0 °C(Predicted)
• 密度：
  1.311±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36/37/39
• 海关编码：
  2922499990
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 2-amino-3-chlorobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 2-amino-3-chlorobenzoate
CAS number: 77820-58-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8ClNO2
Molecular weight: 185.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2-氨基-3-氯苯甲酸甲酯是一个重要的医药和化工中间体，它是合成三唑并嘧啶磺酰胺类除草剂氯酯磺草胺的关键中间体，在许多农药的合成中都有广泛应用。

合成方法

1. 在室温下，于500 mL反应瓶中加入150 g DMF，再依次加入30 g 2-氨基-3-氯苯甲酸（0.175 mol）和17.3 g 碳酸钾（0.125 mol）。

2. 加完后，将混合物冷却至10℃并搅拌0.5 h。随后，在此温度下缓慢滴加22.4 g 硫酸二甲酯（0.178 mol）。

3. 滴加完毕后，升至室温并搅拌反应6 h。

4. 反应结束后，将物料倒入400 mL水中，析出白色固体。搅拌1 h后过滤，滤饼用冷水洗涤、干燥得到31.8 g 2-氨基-3-氯苯甲酸甲酯，收率为95.0%，纯度为97%（HPLC）。

化学性质

2-氨基-3-氯苯甲酸甲酯是一种白色结晶粉末，熔点为35－37℃。

用途

该物质用作医药和农药中间体。

反应信息

• 作为反应物：
  描述：

  2-氨基-3-氯苯甲酸甲酯 在 platinum(IV) oxide 吡啶 、 盐酸 、 sodium tetrahydroborate 、 PPA 、 4 A molecular sieve 、 potassium tert-butylate 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 20.0~120.0 ℃ 、101.33 kPa 条件下， 反应 19.5h， 生成 9-chloro-5-(N-methylamino)-1-[4-[(2-methylbenzoyl)amino]benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine
  参考文献：
  名称：

  7-氯-5-羟基-1- [2-甲基-4-（2-甲基苯甲酰基-氨基）苯甲酰基] -2,3,4,5-四氢-1H-1-苯并ze庚因（OPC-41061）：有力口服活性非肽精氨酸加压素V2受体拮抗剂。

  摘要：

  我们先前报道了一系列苯并ze庚因衍生物作为口服活性非肽精氨酸加压素（AVP）V2受体拮抗剂。在对铅结构OPC-31260进行结构评估和优化后，苯并ze庚因上的7-Cl部分和氨基苯甲酰基部分上的2-CH3引入增强了其口服活性。新的AVP-V2选择性拮抗剂OPC-41061被确定为有效的口服活性剂。

  DOI：

  10.1016/s0968-0896(99)00101-7
• 作为产物：
  描述：

  2,3-二氯苯甲酸 在 四丁基溴化铵 、 氨 、 potassium carbonate 、 copper(l) chloride 作用下， 以 甲醇 、 甲苯 为溶剂， 80.0~130.0 ℃ 、3.04 MPa 条件下， 反应 21.0h， 生成 2-氨基-3-氯苯甲酸甲酯
  参考文献：
  名称：

  METHOD FOR PRODUCING NITROBENZENE COMPOUND

  摘要：

  一种用于制备由通式（2）表示的硝基苯化合物的方法，其中R1和R5相同或不同，每个是卤素原子或另一个官能团，而R2、R3和R4相同或不同，每个是氢原子或另一个官能团，包括在酸性条件下在钨化合物存在下用过氧化氢氧化由通式（1）表示的苯胺化合物，其中R1、R2、R3、R4和R5与上述相同，随后在中性至碱性条件下用过氧化氢氧化。

  公开号：

  US20140163256A1

文献信息

• [EN] COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA<br/>[FR] COMPOSES ET TECHNIQUES DE TRAITEMENT DE LA DYSLIPIDEMIE
  申请人：LILLY CO ELI

  公开号：WO2005037796A1

  公开（公告）日：2005-04-28

  Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.

  式I的化合物，其中n、m、p、q、Y、R1、R2、R3、R4、R5和R6如本文所定义，并且其药物组合物和使用方法被披露为用于治疗动脉粥样硬化及其后遗症。
• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。
• N-arylsulfilimine compounds and their use as catalysts in the
  申请人：Dow AgroSciences LLC

  公开号：US05973148A1

  公开（公告）日：1999-10-26

  N-arylsulfilimine compounds, such as S,S-dimethyl-N-(2,6-dichlorophenyl)sulfilimine, were prepared and found to catalyze the reaction of aromatic sulfonyl chloride compounds, such as 2-chlorosulfonyl-7-fluoro-5-ethoxy[1,2,4]triazolo[1,5-c]pyrimidine, with aromatic amine compounds, such as 2,6-dichloroaniline, to form N-arylarylsulfonamide compounds, such as N-(2,6-dichlorophenyl)-7-fluoro-5-ethoxy[1,2,4]triazolo[1,5-c]-pyrimidine- 2-sulfonamide. The aryl moiety of the N-arylsulfilimine catalyst and the aryl moiety of the aromatic amine compound were generally chosen to be identical.

  N-芳基磺酰亚胺化合物，例如S，S-二甲基-N-（2，6-二氯苯基）磺酰亚胺，已被制备并发现可催化芳香磺酰氯化合物，例如2-氯磺酰基-7-氟-5-乙氧基[1，2，4]三唑[1，5- c]嘧啶，与芳香胺化合物，例如2，6-二氯苯胺，形成N-芳基芳基磺酰胺化合物，例如N-（2，6-二氯苯基）-7-氟-5-乙氧基[1，2，4]三唑[1，5- c]嘧啶-2-磺酰胺。N-芳基磺酰亚胺催化剂的芳基部分和芳香胺化合物的芳基部分通常被选为相同的。
• Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators
  作者：Anthony B. Pinkerton、Satyamaheshwar Peddibhotla、Fusayo Yamamoto、Lauren M. Slosky、Yushi Bai、Patrick Maloney、Paul Hershberger、Michael P. Hedrick、Bekhi Falter、Robert J. Ardecky、Layton H. Smith、Thomas D. Y. Chung、Michael R. Jackson、Marc G. Caron、Lawrence S. Barak

  DOI：10.1021/acs.jmedchem.9b00340

  日期：2019.9.12

  Neurotensin receptor 1 (NTR1) is a G protein coupled receptor that is widely expressed throughout the central nervous system where it acts as a neuromodulator. Neurotensin receptors have been implicated in a wide variety of CNS disorders, but despite extensive efforts to develop small molecule ligands there are few reports of such compounds. Herein we describe the optimization of a quinazoline based

  神经降压素受体1（NTR1）是一种G蛋白偶联受体，在整个中枢神经系统中广泛表达，在其中它充当神经调节剂。神经降压素受体与多种中枢神经系统疾病有关，但是尽管为开发小分子配体付出了巨大的努力，但很少有此类化合物的报道。在这里，我们描述了基于喹唑啉的铅的优化，以得到18（SBI-553），这是一种有效的脑渗透NTR1变构调节剂。
• Constrained compounds as CGRP-receptor antagonists
  申请人：Chaturvedula V. Prasad

  公开号：US20060094707A1

  公开（公告）日：2006-05-04

  The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

  这项发明涵盖了受限的双环和三环CGRP受体拮抗剂，用于识别它们的方法，包含它们的药物组合物，以及它们在治疗偏头痛和其他头痛、神经源性血管舒张、神经源性炎症、热损伤、循环性休克、与绝经期相关的潮红、气道炎症性疾病（如哮喘和慢性阻塞性肺病（COPD））以及其他可以通过CGRP受体拮抗来治疗的疾病的治疗方法。